Latest Science ....
Research Papers and Books
R.D Harvey, N.R. Aransay, N. Isambert, J.-S. Lee, T. Arkenau, J. Vansteenkiste, P.A. Dickinson, K. Bui, D. Weilert, K. So, K. Thomas and K. Vishwanathan (2018) Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. Brit.J. Clin. Pharmacol. 84: 2877-2888. http://dx.doi.org/10.1111/bcp.13753
K. Vishwanathan, P.A Dickinson, K. So, K. Thomas, Y.-M. Chen, J. De Castro Carpeño, A.-M. C Dingemans, H.R. Kim, J.-H. Kim, M.G. Krebs, J. Chih-Hsin Yang, K. Bui, D. Weilert and R.D. Harvey (2018) The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Brit.J. Clin. Pharmacol. 84: 1156-1169. http://dx.doi.org/10.1111/bcp.13534
K. Vishwanathan, P.A. Dickinson, K. Bui, P.A. Cassier, Al. Greystoke, E. Lisbon, V. Moreno, K. So, K. Thomas, D. Weilert, T.A. Yap and R. Plummer (2018) The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small cell lung cancer and in healthy volunteers. J. Clin. Pharmacol. 58: 474-484. http://dx.doi.org/10.1002/jcph.1035
M. Shao, Z. Hussain, H.E. Thu, S. Khan, M. de Matas, V. Silkstone, H-Li. Qin and S.N.A. Bukhari (2017) Emerging trends in therapeutic algorithm of chronic wound healers: Recent advances in drug delivery systems, concepts-to-clinical application, and future prospects. Critical Reviews™ in Therapeutic Drug Carrier Systems: Published online http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2017016957
P.A. Dickinson, T. Flanagan, D. Holt and P.W. Stott (2016) Clinically Relevant Dissolution for Low-Solubility Immediate-Release Products. in "Poorly Soluble Drugs: Dissolution and Drug Release." pp 511-552. Eds: G.K. Webster J. D. Jackson and R.G. Bell. Pan Stanford Publishing. ISBN 9789814745451 http://www.panstanford.com/books/9789814745451.html
Z.T. Rushmia, N. Aktera, R. J. Mowa, M. Afroza, M. Kazib, M.de Matas, M. Rahmana and M.H. Shariarea (2016) The impact of formulation attributes and process parameters on black seed oil loaded liposomes and their performance in animal models of analgesia. Saudi Pharmaceut. 25: 404-412. http://dx.doi.org/10.1016/j.jsps.2016.09.011
P.A. Dickinson, F. Kesisoglou, T. Flanagan, M.N. Martinez, H.B. Mistry, J.R. Crison, J.E. Polli, M.T. Cruañes, A.T.M. Serajuddin, A. Müllertz, J.A. Cook and A. Selen (2016) Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid. J. Pharm. Sci. 105: 3243-3255. http://dx.doi.org/10.1016/j.xphs.2016.07.024
A.W. Dymond, M.-A. Fabre, G.D. James, M. Hirata, S.A. Smith, P.A. Dickinson, M. Dymond and G. Clack (2016) Clinical pharmacology profile of an oral selective androgen receptor down-regulator, AZD3514: Implications on the design of ongoing castrate-resistant prostate cancer clinical studies. Cancer Res. Frontiers. 2: 330-351.
P.A. Dickinson, M.V. Cantarini, J. Collier, P. Frewer, S. Martin, K. Pickup and P. Ballard (2016) Metabolic disposition of osimertinib in rat, dog, and man: insights into a drug designed to bind covalently to a cysteine residue of EGFR. Drug Metab. Dispos. 44: 1201-1212. http://dx.doi.org/10.1124/dmd.115.069203
H. Mistry, M.-A. Fabre, J. Young, G. Clack and P.A. Dickinson (2016) Systems pharmacology modeling of prostate-specific antigen in prostate cancer patients treated with an androgen receptor antagonist and down-regulator. CPT: Pharmacometrics & Systems Pharmacol. 5: 258–263. http://dx.doi.org/10.1002/psp4.12066
M. de Matas, T. De Beer, S. Folestad, J. Ketolainen, H. Lindén, J. Almeida Lopes, W. Oostra, M. Weimer, P. Ohrngren and J. Rantanen (2016) Strategic framework for education and training in quality by design (QbD) and process analytical technology (PAT). Eur. J. Pharm. Sci. 90: 2-7. http://dx.doi.org/10.1016/j.ejps.2016.04.024
D. Planchard, K.H. Brown, D.-W. Kim, S.-W. Kim, Y. Ohe, E. Felip, P. Leese, M. Cantarini, K. Vishwanathan, P.A. Jänne, M. Ranson and P.A. Dickinson (2016) Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother. Pharmacol. 77: 767-776. http://dx.doi.org/10.1007/s00280-016-2992-z.
T. Chan Seem, N.A. Rowson, I. Gabbott, M. de Matas, G.K. Reynolds and A. Ingram (2016) Asymmetric Distribution in Twin Screw Granulation. Eur. J. Pharm. Biopharm. 106: 50-58. http://dx.doi.org/10.1016/j.ejpb.2016.01.013
Invited Talks and Podium Presentations
P.A. Dickinson: BioRAM: connecting the drug product with the patient – from design to optimized product. The 8th APS International PharmSci Conference, University of Hertfordshire, Hatfield, UK. 07 Sept 2017.
P.A. Dickinson: Score sheet, Box 1: Early basic knowledge, starting point. From Blueprint to action: Getting to critical questions and knowledge. Applying the Biopharmaceutics Risk Assessment Roadmap (BioRAM): Patient-Focused Drug Development: Developing critical knowledge with BioRAM and the BioRAM Scoring Grid.The USP Meetings Center in Rockville, MD, USA. 20 July 2017.
M. de Matas: Addressing Unmet Medical Need Using Nanoformulations. Making Pharmaceuticals. Ricoh Arena, Coventry, UK. 26 April 2017
P.A. Dickinson: Introduction to the Biopharmaceutics Risk Assessment Roadmap (BioRAM), Drug Delivery Scenarios and Scoring Grid. EuPAT8, University College Cork, Cork, Ireland. 03 Oct 2016.
P.A. Dickinson: Describing and Illustrating Application of the Biopharmaceutics Risk Assessment Roadmap (BioRAM) and Therapy-Driven Drug Delivery Scenarios. AAPS Webinar: “Fundamentals of the BioRAM” https://www.pathlms.com/aaps/events/479?day=2016-07-20. 20 July 2016.
M. de Matas: Transforming molecules into valued medicines: the domain of the pharmaceutical scientist. 4th Royal Society of Chemistry Early Career Symposium, University of Strathclyde, Glasgow, UK. 24 June 2016.
P.A. Dickinson: Clinically relevant specifications in practice: What have we learned since the QbD Pilot Program? In Roundtable: Clinically Relevant Specifications: Where Are We Now? AAPS Annual Meeting, Orange County Convention Center, Orlando, Fl, USA. 29 Oct 2015.
P.A. Dickinson: Pharmaceutical Quality: The dissolution test and clinically relevant specifications - impact on product development. International Multidisciplinary Symposium on Drug Research and Development, Anadolu University, Eskişehir, Turkey. 17 Oct 2015
M. de Matas: Accelerating the development of drug products using advanced pharmaceutical design tools and manufacturing. International Multidisciplinary Symposium on Drug Research and Development, Anadolu University, Eskişehir, Turkey. 17 Oct 2015
P.A. Dickinson: Design space considerations for dissolution methods. Joint Pharmaceutical Analysis Group Symposium on the Impact of emerging regulatory guidelines on development and commercial activities at PharmSci 2015, East Midlands Conference Centre, Nottingham, UK. 07 Sept 2015.
Oral modified release - beyond once daily. Was also presented by Paul Dickinson at PharmSci 2015. 07 Sept 2015.
For further details please email:
M. de Matas: Transforming promising molecules into valued medicines – the emerging Alderley Park Translational Science Ecosytem (APTrans). At PharmSci 2015, East Midlands Conference Centre, Nottingham, UK. 07 Sept 2015.
Posters and Abstracts
Jake Dickinson, Marcel de Matas, Paul A Dickinson and Hitesh Mistry (2018) Analysis of patient derived xenograft studies in Oncology drug development: impact on design and interpretation of future studies. PKUK, Midland Hotel, Manchester, UK, 21-23 Nov.
K. Vishwanathan, J. C.-Hs. Yang, J.-S. Lee, M. Krebs, P.A. Dickinson, K. Bui, D. Weilert, K. So, K. Thomas and R. D.Harvey (2016) Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291). J. Clin. Oncol. 34: suppl; abstr e14100. http://abstracts.asco.org/176/AbstView_176_166139.html
R.D. Harvey, N. Isambert, S. Rafii, J.F. Vansteenkiste, P.A. Dickinson, K. Bui, D. Weilert, K. So, K. Thomas and K. Vishwanathan (2016) Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin. J. Clin. Oncol. 34: suppl; abstr e14098. http://abstracts.asco.org/176/AbstView_176_166216.html
K. Vishwanathan, P.A. Dickinson, K. Bui, D.K. Weilert, K. So, K. Thomas, E.A. Lisbon and R. Plummer (2015) Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics 2015, Boston, MA, USA.
E, Afriyie, H. Batchelor and M. de Matas (2015) Evaluation of Emerging and Existing Taste Masking Technologies For Paediatric Drug Development. 7th EuPFI Conference. Ramada Plaza Antwerp, Desguinlei, Antwerp. Belgium.
Workshops and Training Courses
P.A Dickinson. PK considerations in setting a Quality Target Product Profile (QTPP) for oral dosage forms and Establishing and using an IVIVC to predict the impact of changes in product on clinical performance - opportunities for post approval changes; advantages/disadvantages of IVIVC. APS Regulatory Essentials II, Burleigh Court, Loughborough, UK. 22 – 23 May 2018.
P.A Dickinson. API Physico-chemical properties: Solid-state and Solution Properties. APS Developability Workshop, Granta Park, Cambridge, UK. 10 April 2018.
M. de Matas, P.A. Dickinson, D. Holt, C. Patterson and G. Reynolds. Recent developments in Quality by Design of pharmaceutical products. Facilitating efficient development of medicinal products that meet the patients need. Alderley Park Conference Centre, Alderley Edge, UK. 18 Oct 2016.
P.A Dickinson. Regulatory Biopharmaceutics. APS Biopharmaceutics Basic Workshop, Burleigh Court, Loughborough, UK. 12 Oct 2016.
P.A. Dickinson. PK considerations in setting a Quality Target Product Profile (QTPP) for oral dosage forms and Establishing and using an IVIVC to predict the impact of changes in product on clinical performance - opportunities for post approval changes; advantages/disadvantages. The Academy of Pharmaceutical Sciences APS Regulatory Essentials Course, Burleigh Court, Loughborough UK. 24 and 25 Nov 2015.
P.A. Dickinson, M. de Matas and B. Aksu. Recent Developments in Quality by Design for Pharmaceutical Products. Point Hotel Barbaros, Istanbul, Turkey. 15 Oct 2015.
For further details please email: